Company Filing History:
Years Active: 2001-2002
Title: Ruth McKernan: Innovator in Psychopharmacology
Introduction
Ruth McKernan is a prominent inventor based in Saffron Walden, GB. She has made significant contributions to the field of psychopharmacology, particularly in the development of novel compounds for the treatment of psychotic disorders.
Latest Patents
Ruth McKernan holds 2 patents that focus on innovative therapeutic agents. Her latest patents include "Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAα5 receptor subtype" and "Antipsychotic use of triazolo-pyridazine derivatives." These patents describe a class of substituted or 7,8-ring fused 1,2,4-triazolo[4,3-b]pyridazine derivatives, which are selective ligands for GABA receptors. They possess high affinity for the α2 and/or α3 subunit, making them beneficial in the treatment and prevention of psychotic disorders, including schizophrenia.
Career Highlights
Ruth McKernan has had a distinguished career, working with Merck Sharp & Dohme Corp. Her research has focused on the development of innovative treatments for mental health conditions, showcasing her commitment to improving patient outcomes.
Collaborations
Throughout her career, Ruth has collaborated with notable colleagues, including William Robert Carling and Angus Murray MacLeod. These partnerships have contributed to her success in advancing psychopharmacological research.
Conclusion
Ruth McKernan's work in the field of psychopharmacology has led to significant advancements in the treatment of psychotic disorders. Her innovative patents and collaborations highlight her dedication to improving mental health therapies.